Filtern
Volltext vorhanden
- ja (2) (entfernen)
Gehört zur Bibliographie
- ja (2)
Dokumenttyp
- Dissertation (2)
Sprache
- Englisch (2) (entfernen)
Schlagworte
- Proteinkinase C (2) (entfernen)
Institut
Platelets are crucial to inhibit extensive blood loss at sites of vascular injury. However, under pathological conditions such as rupture of an atherosclerotic plaque, activated platelets form aggregates that may occlude the vessel. This can lead to heart attack and stroke. Various and complex signaling pathways in the cell are involved in the steps of platelet adhesion, activation and aggregation. Single aspects of these processes were studied in three different subprojects in this work. The Glycoprotein (GP) Ib-V-IX complex is responsible for the first contact of platelets with the vessel wall. Subsequently, GPVI can bind to collagen of the subendothelium, which initiates a signaling cascade leading to platelet activation, aggregation, characterized by integrin activation and granule secretion and platelet procoagulant activity. The latter is characterized by exposed phosphatidylserine (PS) on the platelet surface, which enhances thrombin generation and thereby the coagulation cascade. A controlled regulation of GP receptors on the platelet surface is vital for an intact response of the cell to platelet agonists. In the first subproject described here the regulation of GPV and GPVI on mouse platelets was investigated and it was found that both receptors are shed from the platelet surface in a metalloproteinase dependent manner. However, GPVI is shed upon mitochondrial injury, while GPV cleavage could be observed upon platelet stimulation. The metalloproteinase responsible for GPVI shedding remains unknown whereas the metallproteinase that sheds GPV was identified in this work as being ADAM17. This shows that the expression of both receptors underlies a controlled mechanism regulated through distinct metalloproteinases. In the second subproject the role of protein kinase C (PKC) in platelet activation and procoagulant response was investigated using PKC specific inhibitors. It was found that PKC blockage reduced platelet activation but enhanced platelet procoagulant activity. This is the first time that a dual role in platelet activation and procoagulant activity is defined for PKC. In the third project the role of the small GTPase Rac1 in platelet signaling was studied using conditional Rac1 knock out mice. It is reported here that Rac1 lies downstream of GPVI and is involved in integrin activation and cytsolic Ca2+ changes in vitro and platelet adhesion and thrombus formation in vivo. This is the first time that Rac1 is demonstrated to have a pivotal role in GPVI signaling and furthermore points to a novel, unknown pathway downstream of GPVI.
RS1, a gene product of RSC1A1, is critically involved in cell density-dependent transcriptional down-regulation of SGLT1 in LLC-PK1 cells and in the post-transcriptional down-regulation of SGLT1 in small intestine. RS1 inhibits the release of SGLT1 containing vesicles from the trans-Golgi network and migrates into the nucleus where it inhibits transcription of SGLT1. In the present work we identified a novel 21 amino acids-long nonconventional nuclear localization sequence (RS1 NLS) in porcine RS1 (pRS1) that is necessary and sufficient for nuclear targeting of pRS1. RS1 NLS is framed by two consensus sequences for phosphorylation which are responsible for confluence-dependent regulation of RS1 NLS: a casein kinase 2 (CK2) site in position 348 and a protein kinase C (PKC) site in position 370. Confluence-dependent nuclear targeting was observed with amino acids 342-374 (R-NLS-Reg). Mutation analysis suggested that nuclear targeting is blocked by phosphorylation of serine 370 (PKC) and that phosphorylation of serine 348 (CK2) prevents phosphorylation of serine 370. Because CK2 is down-regulated and PKC is up-regulated during confluence of LLC-PK1 cells, our data suggest that nuclear localization coordinates cell density-dependent changes in transcriptional and post-transcriptional inhibition of SGLT1 expression.